Interference of zinc heparin anticoagulant in determination of plasma magnesium.
Interference of zinc heparin anticoagulant in determination of plasma magnesium.
复制标题
肝素锌抗凝剂对血浆镁测定的干扰。
DOI：
10.1093/clinchem/40.5.848
复制
发表时间：
1994
影响因子：
9.3
通讯作者：
M. Landt
中科院分区：
文献类型：
--
作者：
T. Wilhite;C. Smith;M. Landt
特罗尔 200 mgfdL。注意到这些患者的高血液胆固醇的后续护理，无论是饮食咨询的记录还是血脂谱的测定，包括低密度脂蛋白（LDL）胆固醇。表 1 总结了 126 名胆固醇处于临界高风险（NCEP 定义，胆固醇 200 mg/dL）或高风险类别（NCEP 定义，胆固醇 240 mg/dL）患者的结果。与临床组 H 相比，临床组 I 的患者进行饮食咨询和随访血脂检测的频率更高，其中实验室结果显示超出参考范围的临界高值。通过 x2 分析，这些差异显着，对于分类为临界高的患者，饮食咨询的 P = 0.035；对于分类为高风险的患者，饮食咨询的 P = 0.034；对于分类为高风险的患者的后续血脂检测，这些差异显着，P = 0.035。对于这些患者组来说，将临界高胆固醇值识别为在参考范围内或在参考范围之外是最明显的差异。血清胆固醇值（表1）没有显着差异。两组患者的人口统计数据以及选择他们的两组临床实践的特征没有显着差异。因此，第一组的患者似乎没有比第二组的患者接受更多的治疗，因为他们更年轻、男性、血清胆固醇值更高、有更多的冠心病危险因素，或者在筛查和治疗高胆固醇方面更积极的临床实践。最近的一项研究基于对 37 个州 154 735 名成年人的电话采访，报告称，需要治疗高胆固醇血症的成年人中只有不到三分之一正在接受治疗 (2)——这是成人需要胆固醇的标准。全国胆固醇教育分组专家报告
terol 200 mgfdL. Follow-up care for high blood cholesterol in these patients, either documentationofdietary counseling or the determination of a lipid profile, including low-density lipoprotein (LDL) cholesterol, was noted. Table 1 summarizes the results for the 126 patients with cholesterolin the borderline-high risk (NCEP definition, cholesterol 200 mg/dL) or high-risk categories (NCEP definition, cholesterol 240 mg/dL). The frequency of dietary counseling and follow-up lipid profile testing wasgreater for the patients in clinic group I, where laboratory results indicated borderline-high values as outside the reference range, than in clinic group H. By x2 analysis, these differences are significant at P = 0.035 for dietary counseling in patients classified as borderline-high, and at P = 0.034 for dietary counseling and P = 0.025 for follow-up lipid testing for patients classified as high risk. The identification of borderlinehigh cholesterol values as within the reference range or outsideof the referencerange was the most apparent difference for these groups of patients. The serum cholesterol values (Table 1) did not differ significantly. The demographics of the two groups of patients and the characteristics of the two groups of clinic practices from which they were selected did not differ significantly. Therefore, the patients in group I do not appear to have been treated more often than thosein group II because of being younger, being male, having higher serum cholesterol values, having more CHD risk factors, or being seen in clinical practices that were more aggressive in screening and treating high blood cholesterol. A recent study, based on phone interviews of 154 735 adults in 37 states, reported that fewer than one-third of adults in need of treatment for hypercholesterolemia are receiving treatment (2)-the criteria for needing lesterol in Adults. Report of the National grouped Cholesterol Education Program Expert